Business Matters: Eclipsed by Catastrophe

by G. Steven Burrill at Burrill & Company Despite stimulating and positive news for biotech product approvals and high-value deals this quarter, market performance has been shaped by the terrorist attacks and their aftermath.

Related Content:

Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography

Designs for Bioassays with Plate Location Effects

Liposomes (a Review), Part One: Manufacturing Issues